Transgenic overexpression of human Bcl-2 in islet beta cells inhibits apoptosis but does not prevent autoimmune destruction

Int Immunol. 2000 Jan;12(1):9-17. doi: 10.1093/intimm/12.1.9.

Abstract

Insulin-dependent diabetes mellitus results when > 90% of the insulin-producing beta cells in the pancreatic islets are killed as a result of autoimmune attack by T cells. During the progression to diabetes, islet beta cells die as a result of different insults from the immune system. Agents such as perforin and granzymes, CD95 ligand and tumor necrosis factor-alpha, or cytokines and free-radicals have all been shown to cause beta cell apoptosis. The anti-apoptotic protein, Bcl-2, might protect against some of these stimuli. We have therefore generated transgenic mice expressing human Bcl-2 in their islet beta cells. Although Bcl-2 was able to prevent apoptosis induced by cytotoxic agents against beta cells in vitro, Bcl-2 alone could not prevent or ameliorate cytotoxic or autoimmune beta cell damage in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age of Onset
  • Animals
  • Apoptosis*
  • B7-1 Antigen / biosynthesis
  • B7-1 Antigen / genetics
  • CD8-Positive T-Lymphocytes / immunology
  • Diabetes Mellitus, Type 1 / chemically induced
  • Diabetes Mellitus, Type 1 / immunology*
  • Disease Models, Animal
  • Drug Resistance
  • Humans
  • Interleukin-2 / biosynthesis
  • Interleukin-2 / genetics
  • Islets of Langerhans / immunology*
  • Mice
  • Mice, Transgenic
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis*
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Staurosporine / pharmacology
  • Streptozocin / pharmacology

Substances

  • B7-1 Antigen
  • Interleukin-2
  • Proto-Oncogene Proteins c-bcl-2
  • Streptozocin
  • Staurosporine